Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders..
Read MoreLatest News
Xenon to Report Q2 2025 Financial Results on August 11, 2025
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Joins the Russell 3000® and Russell 2000® Indexes
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View All News >
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
